Patents by Inventor Roberto Patarca

Roberto Patarca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5238839
    Abstract: The present invention relates to genes and their encoded proteins which induce immunological effector cell activation and chemattraction. The proteins of the invention attract subsets of immunological effector cells and stimulate them to express their specialized effector cell functions. Such proteins, termed Ap-1 proteins, are expressed by lymphoid cells, and bind to effector cells such as macrophages and mast cells. In particular, the ApPursuant to the provisions of 35 U.S.C. .sctn.202(c), it is hereby acknoledged that the Governament has certain rights in this invention, which was made in part with funds from the National Institutes of Health.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: August 24, 1993
    Assignee: Dana Farber Cancer Institute
    Inventors: Harvey I. Cantor, Roberto Patarca, Joel L. Schwartz, Gordon Freeman
  • Patent number: 5149785
    Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1), human T cell leukemia virus (HTLV-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.
    Type: Grant
    Filed: February 21, 1990
    Date of Patent: September 22, 1992
    Assignee: Dana-Farber Cancer Institute
    Inventors: Harvey I. Cantor, Roberto Patarca, Gordon J. Freeman
  • Patent number: 4952499
    Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1) human T cell leukemia virus (HTLV)-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.
    Type: Grant
    Filed: February 11, 1988
    Date of Patent: August 28, 1990
    Assignee: Dana-Farber Cancer Institute
    Inventors: Harvey I. Cantor, Roberto Patarca